Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CLBS 201

Next Previous
Drug Profile

CLBS 201

Alternative Names: CD34+ cell therapy; CLBS-201; LSTA-201

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Caladrius Biosciences
  • Developer Lisata Therapeutics
  • Class Cell therapies; Haematopoietic stem cells therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Diabetic nephropathies

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Diabetic-nephropathies in USA (Intra-arterial, Infusion)
  • 10 May 2023 Interim adverse events data from a phase I chronic kidney disease released by Lisata Therapeutics
  • 25 Apr 2023 CLBS 201 is available for licensing as of 25 Apr 2023. https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000032001723000011/clbs-20221231.htm

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top